Retraction to: Oncogene (2014); doi:10.1038/onc.2014.158; published online 9 June 2014
The authors wish to retract this article due to concerns raised regarding some of the data presented in Figures 2, 4, 5, 6 and Supplementary Figures 6 and 7.
According to the data presented in Figures 1, 3 and 7, the major conclusion drawn from this article is still valid: IL-6 secreted by CAFs is causal factor for tamoxifen resistance in luminal breast cancer.
The authors are deeply regretful and apologize to the readers.
Additional information
The online version of the original article can be found at 10.1038/onc.2014.158
About this article
Cite this article
Sun, X., Mao, Y., Wang, J. et al. Retraction Note: IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. Oncogene 33, 4450 (2014). https://doi.org/10.1038/onc.2014.224
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2014.224
This article is cited by
-
The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities
Cellular Oncology (2021)
-
Chemotherapy resistance and stromal targets in breast cancer treatment: a review
Molecular Biology Reports (2020)
-
17β-estradiol upregulates IL6 expression through the ERβ pathway to promote lung adenocarcinoma progression
Journal of Experimental & Clinical Cancer Research (2018)
-
Pre-treatment neutrophil to lymphocyte ratio predicts the chemoradiotherapy outcome and survival in patients with oral squamous cell carcinoma: a retrospective study
BMC Cancer (2016)
